By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

GenSight Biologics 



Paris      France
Phone: +33-1-7621-7220 Fax: n/a


SEARCH JOBS








Company News
GenSight Completes Enrollment Of RESCUE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 8/1/2017 7:49:59 AM
GenSight Reports Long-Term Positive Safety And Visual Acuity Results At Week 96 In Phase I/II Study Of GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 6/14/2017 7:31:50 AM
GenSight Appoints Mohamed Genead As Chief Medical Officer 5/4/2017 10:03:38 AM
Backed By Two Drug Powerhouses, GenSight Alum Launches New Biotech With $40 Million 5/4/2017 5:33:32 AM
GenSight Biologics Reports Full Year 2016 Financial Results 3/13/2017 6:20:14 AM
GenSight Biologics Completes Enrollment Of REVERSE Phase III Study Of GS010 In The Treatment Of Leber’s Hereditary Optic Neuropathy 2/21/2017 6:35:38 AM
GenSight Biologics Receives FDA Orphan Drug Designation For GS030 In Retinitis Pigmentosa 1/31/2017 11:19:49 AM
GenSight Biologics Reports Sustained Visual Acuity Gain At 78 Weeks In Its Phase I/II Study With GS010 For The Treatment Of Leber’s Hereditary Optic Neuropathy (LHON) 12/20/2016 10:42:34 AM
GenSight Biologics Receives Approval To Include Teenage Patients In RESCUE And REVERSE Phase III Trials With GS010 In Leber’s Hereditary Optic Neuropathy 9/8/2016 11:06:52 AM
GenSight Biologics Receives Orphan Drug Designation And Advanced Therapy Medicinal Product Classification In Europe For GS030 In Retinitis Pigmentosa 9/1/2016 1:08:31 PM
12
//-->